Viracta Therapeutics Inc (NASDAQ: VIRX) is -68.04% lower on its value in year-to-date trading and has touched a low of $0.18 and a high of $1.31 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VIRX stock was last observed hovering at around $0.19 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.18, the stock is -17.09% and -19.39% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.47 million and changing -4.36% at the moment leaves the stock -68.32% off its SMA200. VIRX registered -73.13% loss for a year compared to 6-month loss of -77.92%. The firm has a 50-day simple moving average (SMA 50) of $0.2262 and a 200-day simple moving average (SMA200) of $0.57695.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -21.30% gain in the last 1 month and extending the period to 3 months gives it a -58.71%, and is -9.71% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.48% over the week and 9.23% over the month.
Viracta Therapeutics Inc (VIRX) has around 40 employees, a market worth around $7.18M and $0.00M in sales. Distance from 52-week low is 0.39% and -86.09% from its 52-week high. The company has generated returns on investments over the last 12 months (-1697.34%).
The EPS is expected to grow by 32.07% this year
46.0 institutions hold shares in Viracta Therapeutics Inc (VIRX), with institutional investors hold 50.26% of the company’s shares. The shares outstanding are 39.09M, and float is at 27.71M with Short Float at 3.98%. Institutions hold 48.83% of the Float.
The top institutional shareholder in the company is BVF INC/IL with over 3.61 million shares valued at $1.97 million. The investor’s holdings represent 9.192 of the VIRX Shares outstanding. As of 2024-06-30, the second largest holder is CITADEL ADVISORS LLC with 1.52 million shares valued at $0.83 million to account for 3.8659 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 1.16 million shares representing 2.9531 and valued at over $0.63 million, while SAMSARA BIOCAPITAL, LLC holds 1.7539 of the shares totaling 0.69 million with a market value of $0.37 million.
Viracta Therapeutics Inc (VIRX) Insider Activity
The most recent transaction is an insider sale by Chevallard Daniel R., the company’s CFO and COO. SEC filings show that Chevallard Daniel R. sold 3,405 shares of the company’s common stock on Feb 27 ’24 at a price of $0.73 per share for a total of $2493.0. Following the sale, the insider now owns 0.1 million shares.
Viracta Therapeutics Inc disclosed in a document filed with the SEC on Nov 30 ’23 that Rothera Mark (President and CEO) bought a total of 52,094 shares of the company’s common stock. The trade occurred on Nov 30 ’23 and was made at $0.49 per share for $25734.0. Following the transaction, the insider now directly holds 52094.0 shares of the VIRX stock.
Still, SEC filings show that on Dec 01 ’23, Rothera Mark (President and CEO) acquired 47,906 shares at an average price of $0.49 for $23627.0. The insider now directly holds 100,000 shares of Viracta Therapeutics Inc (VIRX).
